Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma

Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma

Abstract. The management of pancreatic cancer has dramatically changed since the first major randomized trial published in 2001 by the European Study Group for Pancreatic Cancer (ESPAC) stimulated the development of multimodality oncosurgical therapies. ESPAC-1 demonstrated a survival improvement fr...

Full description

Bibliographic Details
Main Authors: Carl S. Leonhardt, MD, Benno Traub, MD, Thilo Hackert, MD, Ulla Klaiber, MD, Oliver Strobel, MD, Markus W. Büchler, MD, John P. Neoptolemos, MA, MD, MB, BChir, FRCS, FMedSci
Format: Article
Language:English
Published: Wolters Kluwer Health/LWW 2020-03-01
Series:Journal of Pancreatology
Online Access:http://journals.lww.com/10.1097/JP9.0000000000000040

Internet

http://journals.lww.com/10.1097/JP9.0000000000000040

Similar Items